Patient-Friendly Explanation

Gastroparesis means the stomach empties more slowly than normal, which causes early fullness, nausea and sometimes vomiting. GLP-1 medicines such as semaglutide and tirzepatide are designed to slow stomach emptying, so mild fullness is expected, but a minority of people develop more persistent symptoms. Speak to your doctor if you have ongoing vomiting, severe abdominal pain or cannot keep fluids down.

Clinical Definition

GLP-1 receptor agonists and dual GIP/GLP-1 agonists delay gastric emptying through vagal and enteric mechanisms, contributing to satiety and postprandial glucose control. Most patients tolerate this well, but a subset report persistent nausea, early satiety, bloating and vomiting; pre-existing diabetic gastroparesis, previous bariatric surgery and rapid dose escalation raise the risk. Severe presentations include dehydration and rarely aspiration during anaesthesia; evaluation may include gastric emptying scintigraphy, and management involves dose reduction or temporary pause, smaller low-fat meals and antiemetics.

Why It Matters

Distinguishing expected delayed emptying from true gastroparesis prevents needless discontinuation of effective therapy while catching the rare serious case. It also informs peri-operative fasting guidance and monitoring in patients with diabetic autonomic neuropathy.